Arnon Nagler, MD, MSc, Chaim Sheba Medical Center, Tel-Hashomer, Israel, discusses the results of the survey evaluating minimal residual disease (MRD) testing for acute lymphoblastic leukemia (ALL) in the European Blood and Marrow Transplantation (EBMT) transplant centers. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).